Protocol Ledger

NCT04706507 · Phase III · TERMINATED

Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

Interventional Phase III clinical trial protocol NCT04706507 sponsored by Fred Hutchinson Cancer Center in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-29 Enrollment: 205 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04706507
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)205 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04706507
Protocol FieldVerified Registry Value
NCT IdentifierNCT04706507
Consolidated Lead SponsorFred Hutchinson Cancer Center
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment205 participants (ACTUAL)
Registered Start Date2021-06-29
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fred Hutchinson / UW Medicine across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI